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Background/Aims: Aim of this retrospective study was to analyze the efficacy, safety, and predictors of treatment
success for first-generation-PI triple therapies, including either boceprevir or telaprevir, in a mono-centric “real-life”
setting with respect to SVR 24.
Patients: 131 patients (102 patients telaprevir, 29 patients boceprevir) were treated. Of these, 33/131 patients were
treatment naïve, 72/131 patients had been pretreated with PEG-IFN/RBV (PR) (thereof: 36 with non-response, 30
with relapse, 6 unknown), and 26/131 patients previously had received non-pegylated interferon. 96/131 patients
were infected with HCV genotype 1b. 41/131 patients had liver cirrhosis.
Results: 95/131 (73%) patients achieved SVR 24. SVR rates for subgroups were: 26/33 (79%) for treatment naïve, 25/30
(83%) for PR-relapse, 20/36 (56%) for PR-non-response, 21/26 (81%) for non-PR pretreated patients, (26/41) 63%
for patients with liver cirrhosis, 23/35 (66%) genotype 1a, 72/96 (75%) genotype 1b. Predictors of SVR 24 were
eRVR and a negative viral load at PI-treatment week 4 (p < 0.0001), negative predictors were quantifiable HCV viral
load at PI-treatment week 4 (p < 0.0001), baseline platelet count < 100/nl (p < 0.0001), and previous PR-non-response
(p = 0.006). 33/131 (25%) patients discontinued treatment prematurely, of those 14/131 (11%) patients due to virological
failure. Side effects were frequent (anemia 59/131 [45%], severe infections 6/131 [5%]).
Conclusions: According to our SVR 24 results, efficacy of PI-based triple therapy in our “real-life” cohort is comparable
to the large multi-centric clinical trials. Pronounced side effects are frequent during therapy and often need complex
therapeutic interventions. Since new DAA are available, it is open to discussion, if first-generation PI-triple therapy is no
longer indicated at all.
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The prevalence of hepatitis C virus (HCV) infection in
western countries is in the range of 0.2-2%, while world-
wide about 170 million people are threatened by the dis-
ease. In Europe and Northern America, HCV genotype 1
infections are most prevalent with figures of about 50%
[1-3]. From the turn of the millennium until 2011 the
standard of care for treatment of HCV consisted of
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unless otherwise stated.thus achieving sustained viral response (SVR) rates of
about 50% for HCV genotype 1 patients [4-8]. Unfortu-
nately, many HCV genotype 1 patients concluded the
dual therapy without success and later on suffered from
severe complications of advanced liver disease. There-
fore, HCV genotype 1 infected patients were assigned as
a “difficult-to-treat” group of patients, and a substantial
fraction eventually had to undergo liver transplantation,
or even finally deceased [9]. Therefore, as in HIV and
HBV treatment, direct-acting antiviral agents (DAA)
were desired. Several drug classes were in development:
the (i) polymerase-, (ii) NS5A-, and (iii) protease inhibi-
tors (PI). Finally, in 2011, first-generation PI boceprevir. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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thorities. PI-containing combinations constituted the
treatment standard until early 2014 [10-14]. By adding
BOC or TVR to the combination of PEG-IFN plus RBV
(PR), SVR rates in treatment naïve patients were found
to be significantly raised in clinical trials to up to 67-
68% (BOC), and 75% (TVR) compared to a sole PR
treatment exhibiting an SVR rate of only around 50%
[4,5,10,13]. However, when compared to the hitherto PR
standard regimen, the superb antiviral activity of these
new triple therapy regimens was counteracted by aggra-
vated side effects, namely anemia, bacterial infections,
and dermatological toxicity.
Now, in the dusk of the era of first generation PI, with
approval of (i) the first-in-class polymerase inhibitor
Sofosbuvir in January of 2014, (ii) the second-generation
protease inhibitor Simeprevir in May 2014 (in Europe,
earlier in the US), and the approval of (iii) the NS5A in-
hibitors Daclatasvir and Ledipasvir later this year [15],
we here now summarize our experiences with first-
generation PI being obtained in an experienced tertial
referral center. Aim of this retrospective analysis was
(i) to gather data on the antiviral efficacy and safety of
PI-based triple therapy with respect to SVR 24 weeks
after conclusion of treatment (SVR 24), and (ii) to de-
termine predictors of SVR 24, or premature discontinu-
ation, respectively, in the “real-life” setting of a large
single center cohort in the hands of an experienced
treatment center.
Patient characteristics
The clinical features of our study cohort are presented
in Table 1. This retrospective analysis includes all 131
consecutively recruited patients, who were set on a PI-
triple therapy including PR and TVR (102 patients), or
PR and BOC (29 patients) between July 2011 and May
2012 at our center. From July 2011 until beginning of
September 2011 all patients were treated with BOC-
triple therapy, since TVR was not approved then. How-
ever, after approval of TVR in late September 2011,
almost all patients were treated with the TVR-triple
therapy at our center. This special management of
patients explains the disproportion in numbers of both
groups of patients.
The treatment course for TVR-based triple therapy
consisted of 12 weeks of triple therapy with TVR and
PR, followed by a dual therapy with PR. The length of
that second dual therapy period was variable, according
to the approved treatment recommendations: if patients
were (i) treatment naïve or relapsers to a classical dual
treatment regimen consisting of PR alone, (ii) had no
liver fibrosis of higher grade, and (iii) exhibited a nega-
tive HCV viral load (Cobas AmpliPrep/Cobas TaqMan
HCV Test, Roche Diagnostics GmbH, Mannheim,Germany; lower limit of detection [LLOD] and lower
limit of quantification [LLOQ] 15 IU/ml,) after 4 weeks
of triple therapy, they were eligible for treatment short-
ening down to altogether 24 weeks; if not so, treatment
was extended to 48 weeks. According to guidelines,
those patients with non-pegylated IFN as last treatment
were eligible for treatment shortening as well, even if
they were classified as non-responders as last treatment
response. Patients, who presented with a HCV viral
load above 1000 IU/ml at treatment week (TW) 4 or at
any time afterwards had to discontinue treatment pre-
maturely; the same applied for patients, who exhibited
a rise in HCV viral load of 1 log10 above a previous
nadir viral load.
BOC-based triple therapy was conducted in accord-
ance with the European and German regulations (which
differ from the treatment schedule in the US): following
a “lead-in” phase of four weeks of sole PR treatment,
BOC was added to the dual treatment regimen. Duration
of triple therapy differed according to the respective
fibrosis grade and previous treatment responses: if pa-
tients were treatment naïve and achieved a HCV RNA
level below LLOD after TW 8, treatment duration could
be shortened to 28 weeks altogether. When a patient
was treatment naïve, and failed to achieve a HCV RNA
level below LLOD at TW 8, but reached this goal there-
after (until TW 24) and additionally had no proven liver
cirrhosis, then BOC could be abandoned after TW 36,
followed by additional 12 weeks with PR alone until TW
48. If the patient had been on PR previously (resulting in
virological relapse, breakthrough, or confirmed “partial
response”), demonstrated a HCV viral load below LLOD
after TW 24, and additionally had no proven liver cir-
rhosis, then BOC could be abandoned after TW 36,
followed by additional 12 weeks with PR alone until TW
48. In patients with liver cirrhosis and/or previous non-
response (null-response) to a PR treatment, BOC had to
be given in addition to PR from TW 4 on to TW 48.
Patients, who presented with a HCV viral load above
100 IU/ml at TW 12 or at any time afterwards had to
discontinue treatment prematurely; the same applied for
patients, who exhibited a rise in HCV viral load of one
log10 above a previous nadir viral load. Due to our status
as a tertiary referral center (being quite used to referrals
of cases exhibiting incomplete data on viral loads in pre-
vious treatment attempts performed “outside”), we a
priori did not differentiate between so called “null-
response” and “partial response” patients, and subsumed
those patients as “non-response” patients, a procedure
which was commonly accepted in the pre-PI era.
In response to anemia, we administered EPO based on
individual decisions as follows: (i) if patients were symp-
tomatic or (ii) if we assumed that RBV dose reduction
could be avoided or (iii) if we assumed that we would
Table 1 Characteristics of study cohort patients
Demographics TVR BOC
n 102 29
Age (years)* 53 (45.5-60) 50 (37.5-57.5)
Sex Male/Female/total 53/49/102 20/9/29
Weight (kg)* 77 (64–85) 78 (68.5-86)
BMI (kg/m2)* 26 (23.1-28.7) 26 (24–28)
Baseline viral characteristics
Genotype 1a/1b n;%/n;% 28; 27%/74; 73% 7; 24%/22; 76%
Baseline viral load (IU/ml)* 1.175 Mio (462,250-3.075 Mio) 1.02 Mio (503,000-4.005 Mio)
Baseline viral load≤ 800.000 IU/ml n;% 35; 34% 11; 38%
Baseline viral load≥ 800.000 IU/ml n;% 66; 65% 18; 62%
Baseline viral load missing n;% 1; 1% 0
Assessment of severity of liver disease
Liver histology available n;% 60; 59% 17; 59%
Fibrosis score Ishak* 4 (2–5) 4 (2–5)
Activity score Ishak* 8 (6–9) 7 (3–8)
Cirrhosis (fibrosis score Ishak≥ 5) n;% 29; 28% 6; 21%
Clinical signs of advanced liver disease, but no histology** n;% 5; 5% 1; 3%
Treatment history (last treatment***)
Treatment naïve n;% 24; 24% 9; 31%
PEG-IFN/RBV, overall n;% 58; 57% 14; 48%
PEG-IFN/RBV, non-response+ n;% 28; 27% 8; 28%
PEG-IFN/RBV, relapse n;% 25; 25% 5; 17%
PEG-IFN/RBV, unknown response n;% 5; 5% 1; 3%
Non-PEG IFN overall++ n;% 20; 20% 6; 21%
Non-PEG IFN ± RBV, non-response n;% 9; 9% 4; 4%
Non-PEG IFN ± RBV, relapse n;% 9; 9% 2; 2%
Non-PEG IFN ± RBV, unknown response n;% 2; 2% 0
Current treatment characteristics
PEG-IFN 2a/2b n;%/n;% 96; 94%/6; 6% 27; 93%/2; 7%
RBV baseline dosage mg/day* 1200 (1000–1200) 1200 (1000–1200)
RBV baseline dosage per body weight mg/kg body weight/day* 14.6 (14.1-15.65) 15 ± 2.6 (14.4-15.9)
Baseline clinical chemistry
Leukocytes (/μl)* 5990 (4842–7295) 6645 (5330–8410)
Hemoglobin (g/dl)* 14.7 (13.8-15.9) 15.3 (14.4-15.9)
Platelets (thousand/μl)* 186 (143–257) 227 (182–259)
Creatinine (mg/dl)* 0.7 (0.6-0.8) 0.7 (0.6-0.8)
GFR MDRD (ml/minute)* 102 (90–119) 112.8 (101.6-126.4)
Total Bilirubin (mg/dl)* 0.7 (0.6-0.9) 0.7 (0.5-0.9)
Quick (%)* 105 (95–112) 108 (98–115)
INR INR* 1 (0.9-1) 1 (0.9-1)
GPT IU/l* 69 (44–87) 64 (46–97)
*Data are presented as medians (interquartile ranges in parentheses); **e.g. esophageal varices, ascites, distinct sonographical signs of portal hypertension or liver
cirrhosis; ***treatment with highest antiviral activity, if low dose PEG-IFN, then neglected; +including “null-responders”, “partial responders”, and one patient with
“viral breakthrough”; ++including interferon alpha 2a, interferon alpha 2b, and consensus interferon. Abbreviations: BMI Body mass index, GFR MDRD Gomerular
filtration rate modification of diet in renal disease, GPT Glutamate-pyruvate transaminase, INR International normalized ratio, PEG-IFN Pegylated interferon,
RBV Ribavirin.
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applying EPO. Granulocyte-colony stimulating factor
(G-CSF) was given if patients exhibited leukocyte counts
below 1000/μL.
Baseline laboratory values are shown in Table 1. 4/131
patients presented with leukopenia (leukocyte count <
2500/μl), 15/131 patients had a moderate (platelets <
100/nl) and 2/131 a severe thrombopenia (platelets < 50/
nl). All of them, except 3 patients with moderate throm-
bopenia, were in the TVR patient group. One of those
patients had immune-mediated thrombopenia. Transam-
inases were found to be elevated in 113/131 patients
(GPT > 35 IU/ml: TVR-group 87/102; BOC-group 26/29,
respectively). 3/131 patients exhibited a Quick value
below 60% (one of those was on phenprocoumon for
atrial fibrillation); all of them were in the TVR subset of
patients. Baseline and follow-up data of albumin levels
were available only on an occasional basis. Data were
statistically analyzed using Microsoft Office Excel, Graph
Pad Prism 6.0, and SPSS 21.
Results
Subgroup analysis of sustained virological response (SVR
24) rates
Overall viral response rates and SVR 24 rates according
to previous treatment response (naïve, relapse, non-
response, non-pegylated IFN pretreated) are shown in
Figures 1 and 2. In the overall cohort, 73% (95/131) of
patients achieved SVR 24. Four patients were lost to
follow-up. Of those four patients, 2 had reached SVR 12,
but then did not show up for follow-up visits. SVR 24
rates in patients, (i) who were treatment naïve, (ii)Figure 1 Overall treatment outcome in the TVR and BOC patient
subgroups (ITT). *two of those patients reached SVR 12, but did not
show up to SVR 24; **four patients reached SVR 24 despite premature
discontinuation and therefore were added to the SVR 24-column; #one
patient lost to follow-up; ##one patient reached SVR 24 despite
premature discontinuation and therefore was added to the SVR
24-column. Abbreviations: BOC: boceprevir, TVR: telaprevir; SVR:
sustained virological response.suffered from virological relapse after a PR treatment, or
(iii) had a non-PEG-IFN-based previous treatment,
ranged from 77-84%, irrespective of the administered
type of PI-triple therapy.
Predictors of SVR 24
For evaluation of predictors of SVR 24, see Tables 2 and
3. By univariate analysis of the overall cohort, extended
rapid virological response (eRVR; p < 0.0001) and a nega-
tive viral load at PI-TW 4 (p < 0.0001) were significantly
associated with an increased likelihood of SVR 24, while
a baseline platelet count of < 100/nl (p < 0.0001), a viral
load above LLOQ at TW 4 (p < 0.0001), and a previous
non-response to PR therapy (p = 0.006) were negative
predictors of SVR 24. In the TVR-group of patients, the
best positive predictor for SVR 24 was an eRVR, being
defined as negative HCV-viral loads (below LLOD) at
both TW 4, and 12, respectively. In our TVR-cohort, 64
out of 102 (63%) patients met those criteria. When
TVR-treated patients achieved eRVR, the probability of
achieving a SVR 24 later on was 91% (58/64 patients, p
< 0.0001, Fisher’s exact test). For BOC triple therapy,
due to the different treatment schedule, eRVR is defined
as negative HCV-viral loads at both TW 8, and 24,
respectively. In our BOC-cohort, patients, who achieved
eRVR had a probability of 81% (13/16 patients) of
achieving a SVR 24.
For the overall cohort, the probability of achieving a
SVR 24 was lower in patients, who had a detectable, but
not quantifiable viral load (below LLOQ) at TW 4: In
this subset of patients, only 69% (20/29 patients)
achieved a SVR 24 (p = 0.0193, Fisher’s exact test). Rea-
sons for treatment failure were virological failure (n = 4),
premature discontinuation (n = 4), and relapse (n = 1).
At least in our cohort, for TVR-patients the following
prediction could be made: if patients showed a quantifi-
able viral load 4 weeks after onset of PI-administration
(viral load above LLOQ at TW 4), no patient (0/7
patients) achieved a SVR 24 later on, in all cases due to
virological failure (p < 0.0001, Fisher’s exact test).
15 out of 131 patients (12 patients TVR-treated, 3 pa-
tients BOC-treated, respectively) had platelet counts
below 100/nL at baseline thus resembling an extra-“dif-
ficult-to-treat” group of patients [16]. Of those, just
two patients achieved SVR 24 after regular completion
of a full treatment course (13%), and thus had a signifi-
cantly lower SVR 24 rate than others (p = 0.0001, Fisher’s
exact test).
Patients who previously had shown a virological non-
response to PR treatment, exhibited lower SVR 24 rates
than other subgroups (p = 0.0075), especially in the BOC
group of patients (p = 0.0014, Fisher’s exact test).
Almost all patients with a virological failure during
PI-triple therapy (13/14 patients) had a high viral load
Figure 2 SVR 24 rates with respect to previous treatment response (ITT). Abbreviations: BOC: boceprevir, IFN: interferon, TVR: telaprevir; PR: pegylated
interferon/ribavirin, RBV: ribavirin, SVR: sustained virological response. Missing patients had an unknown treatment outcome in a previous treatment.
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statistical significance was achieved with respect to pre-
dictability of SVR 24, at least in our cohort. Older
patients (> 60 years), knowingly prone to side effects,
are “difficult-to-treat” patients [17]. However, in our
cohort, irrespective of previous treatment status, we
could achieve favorable SVR rates in this subgroup of
patients (73% with TVR, and 4 out of 5 patients with
BOC, respectively).
In the TVR-subset, patients with liver cirrhosis
achieved SVR 24 rates of 71%, and remarkably, in the
subgroup of TVR-patients, who had both liver cirrho-
sis and were of older age, a SVR 24 rate of 67% (8/
12 patients) could be achieved. In the BOC group of
patients with liver cirrhosis 2 out of 7 patients
achieved SVR 24.
Multivariate analysis identified eRVR, a baseline
platelet count of > 100/nl, and previous response
status as independent predictors of higher SVR 24
rates (see Table 3 for odds ratios, and confidence
intervals).Response guided therapy
In the TVR-group at baseline 48 of the 102 patients had
no fundamental contraindications for a shortened treat-
ment course of 24 weeks, as e.g. liver cirrhosis or previ-
ous non-response to a PR therapy. Of those, 34 out of
48 (71%) were found to reach a HCV viral load below
LLOD at TW 4, thus meeting the basic requirement for
treatment shortening. In fact, treatment shortening fi-
nally was implemented in only 26 out of 48 patients
(54%). 25 out of those 26 patients (96%) achieved SVR
24, whereas 1 patient was lost to follow-up. With BOC-
triple therapy, 4 out of 7 patients, who had no basic con-
traindications for shortening of treatment at baseline,
met all criteria at TW 8 for an implementation of such a
procedure. Of those, two patients achieved SVR 24,
while one patient suffered from virological relapse and
another patient was lost to follow-up.
Virological failure
Altogether, 14 of the 131 patients (11%) had to stop PI-
based triple therapy due to on-treatment virological
Table 2 Predictive model of SVR analyzed for all patients treated with PI-triple therapy (TVR + BOC; n = 131), and
analyzed for subgroups of patients treated with TVR (n = 102) or BOC (n = 29)
SVR 24 p value SVR 24 p value SVR 24 p value
(TVR + BOC) (TVR + BOC) (TVR) (BOC) (BOC)
(n/N;%#) (n/N;%#) (TVR) (n/N;%#)
Viral kinetics##
eRVR 71/80; 89% <0.0001 58/64; 91% <0.0001 13/16; 81% 0.0969
Non-eRVR 23/45; 51% 18/34; 53% 5/11; 45%
PI-TW 4 < LLOD 72/83; 87% <0.0001 59/67; 88% 0.0005 13/16; 81% 0.0969
PI-TW 4 > LLOD 22/42; 52% 17/31; 55% 5/11; 45%
PI-TW 4 < LLOD 72/83; 87% 0.0193 59/67; 88% 0.0619 13/16; 81% 0.5528
PI-TW 4 minimal viral load (> LLOD, < LLOQ) 20/29; 69% 17/24; 71% 3/5; 60%
PI-TW 4 viral load < LLOQ 92/112; 82% <0.0001 76/91; 84% <0.0001 16/21; 76% 0.1358
PI-TW 4 viral load > LLOQ 2/13; 15% 0/7; 0% 2/6; 33%
Baseline demographic parameters
Fibrosis
Liver Cirrhosis (Ishak 5 + 6) 26/41; 63% 0.0931 24/34; 71% 0.3331 2/7; 29% 0.0712
No Liver Cirrhosis (Ishak 1–4) 70/90; 78% 54/68; 79% 16/22; 73%
Sex
Male 49/73; 67% 0.1675 39/53; 74% 0.6541 10/20; 50% 0.0959
Female 46/58; 79% 38/49; 78% 8/9; 89%
Age
Patients≥ 60 years 23/31; 74% 1.0000 19/26; 73% 0.6053 4/5; 80% 0.6221
Patients < 60 years 73/100; 73% 59/76; 78% 14/24; 58%
Baseline viral load###
High viral load (>800.000 IU/ml) 60/84; 71% 0.6804 49/66; 74% 0.8126 11/18; 56% 0.6942
Low viral load (<800.000 IU/ml) 35/46; 76% 27/35; 77% 8/11; 73%
Genotype
1a 23/35; 66% 0.3763 19/28; 68% 0.3068 4/7; 57% 1
1b 72/96; 75% 58/74; 78% 14/22; 64%
Baseline platelet count
Platelets > 100/nl 91/116; 78% 0.0001 73/90; 81% 0.0012 18/26; 69% 0.0452
Platelets < 100/nl 4/11; 36% 4/12; 33% 0/3; 0%
Previous non-response vs. other*
Non-response 20/36; 55% 0.0075 19/28; 68% 0.2948 1/8; 13% 0.0014
Other 76/95; 80% 59/74; 80% 17/21; 81%
Fisher’s exact test was used. Significant calculations (p < 0.05) are printed bold. #number of patients who achieved SVR 24 in category/total number in category.
##6 patients (4 TVR-, 2 BOC-patients) had no measurement of viral load at TW 4 due to premature treatment discontinuation or because they did not show up for
scheduled visit; therefore they were excluded from analysis. ###1 baseline viral load missing. *Other (includes treatment naïve, relapsers, unknown response,
pretreatment with other interferon than pegylated interferon). Abbreviations: BOC Boceprevir, eRVR Extended rapid virological response, LLOD Lower limit of
detection, LLOQ Lower limit of quantification, PI Protease inhibitor, SVR Sustained virological response, TVR Telaprevir, TW Treatment week.
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fered from virological relapse during follow-up, all of
those occurred between EOT and first follow-up, which
was routinely done 12 weeks after EOT. 10 of the 102
TVR-patients (10%) suffered from on-treatment viro-
logical failure (4 patients meeting the futility rule of a
viral load > 1000 IU/ml, 3 patients with virological break-
through at TW 12, 18, and 24, respectively, and 3patients with rising viral loads after having reached a
nadir). Additionally, 1 patient experienced a virological
relapse. In the TVR-group of patients no virological fail-
ure occurred after TW 24. In the BOC-group of pa-
tients, altogether 4 out of 29 patients (14%) experienced
an on-treatment virological failure: 3 patients suffered
from virological non-response, when meeting the futility
rule (HCV viral load > 100 IU/ml) at TW 12 or later.
Table 3 Univariate and multivariate models for prediction of SVR (for all patients treated with PI-triple therapy; n = 131)
Univariate analysis Multivariate analyses**
Odds ratio (95% CI) Wald p value Odds ratio (95% CI) Wald p value
Viral kinetics
eRVR vs. no eRVR 8.875 (3.66, 21.51) <0.0001 8.875 (3.66, 21.51) <0.0001
PI-TW 4 < LLOD vs. > LLOD 7.115 (3.04, 16.65) <0.0001 n/a***
PI-TW 4 viral load > LLOQ vs. < LLOQ 0.049 (0.01, 0.24) <0.0001 n/a***
Baseline demographic parameters
Fibrosis
Liver Cirrhosis (Ishak 5 + 6) vs. no Liver Cirrhosis (Ishak 1–4) 0.528 (0.24, 1.18) 0.118 0.858
Sex
Male vs. female 0.533 (0.239, 1.187) 0.123 0.194
Age
Patients < 60 years vs. ≥ 60 years 0.894 (0.358, 2.23) 0.811 0.751
Baseline viral load
High viral load (>800.000 IU/ml) vs. Low viral load (<800.000 IU/ml) 0.679 (0.29, 1.58) 0.367 0.165
Genotype
1a vs. 1b 1.565 (0.678, 3.62) 0.294 0.308
Baseline platelet count
Platelets < 100/nl vs. > 100/nl 0.1 (0.029, 0.341) <0.0001 0.112 (0.032, 0.394) 0.001
Previous treatment response
Non-response vs. other* 0.313 (0.137, 0.715) 0.006 0.357 (0.147, 0.867) 0.023
Significant calculations (p < 0.05) are printed bold. For absolute numbers see Table 2. *Other (includes treatment naïve, relapsers, unknown response, pretreatment
with other interferon than pegylated interferon). **Multivariate analysis was performed twice: first, all shown parameters were included, showing significant results
for “eRVR vs. no eRVR”, and “Platelets < 100/nl vs. > 100/nl”, secondly multivariate analysis was conducted only with “baseline demographic parameters” (excluding
parameters of viral kinetics), showing significant results for “Platelets < 100/nl vs. > 100/nl”, and additionally “Non-response vs. other”. ***“PI-TW4 < LLOD vs. > LLOD” and
“PI-TW 4 viral load > LLOQ vs. < LLOQ” both had to be excluded from the multivariate analysis due to strong collinearity with “eRVR vs. no eRVR”. The width of the
confidence intervals might be due to the limited number of cases in our sample. Abbreviations: eRVR Extended rapid virological response, LLOD Lower limit of detection,
LLOQ Lower limit of quantification, PI Protease inhibitor, SVR Sustained virological response, TW Treatment week, n/a Not applicable.
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TW 48. Additionally, 3 patients (10%) experienced a
virological relapse between EOT and first follow-up visit.
Discontinuation of treatment
Altogether, 33 out of 131 (25%) patients prematurely dis-
continued PI-triple therapy. Of those, 14 discontinued
due to virological failure (see above) and 18 due to side
effects. One additional patient belonging to the TVR-
patient cohort was treated after having been listed for
liver transplantation due to hepatocellular carcinoma.
This patient qualified for an exceptional MELD score be-
fore and during therapy. At TW 36 an organ offer by
EUROTRANSPLANT had been accepted for this patient
followed by successful transplantation. This patient
therefore discontinued treatment prematurely. Neverthe-
less, this patient stayed HCV negative thereafter in a
sustained fashion (SVR 24). In the TVR-group of
patients, 14 other patients prematurely discontinued
complete treatment: 4 patients due to rash, 3 patients
due to infections, 3 patients due to intolerance of the
treatment, 2 patients due to hepatic decompensation, 1patient due to intracerebral bleeding, and 1 patient due
to lung cancer. Despite their premature discontinuation
of treatment, three of those 14 patients achieved a SVR
24, including one patient, who had to undergo LTx due
to hepatic decompensation at TW 4.
In the BOC-group of patients, 4 patients discontinued
treatment prematurely: Two patients due to intolerance to
the treatment, one patient due to non-treatment associated
posttraumatic stress syndrome, and one patient due to
pruritus. The latter one nevertheless achieved a SVR 24.
Remarkably, 14 out of the 18 discontinuations which
had been due to side effects had occurred in patients of
older age (≥ 60 years), or in patients with liver cirrho-
sis, among those 5 patients exhibiting a liver cirrhosis
at age ≥ 60 years. This again emphasizes the “difficult-
to-treat” status of these subgroups.
In 4 of the 102 TVR-treated patients TVR alone was
withdrawn prematurely due to development of a severe
rash. Additionally, one of the 29 BOC-treated patients
discontinued taking BOC due to diarrhea. Subsequently,
PR treatment was continued in all patients. All five pa-
tients achieved SVR 24 later on.
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Side effects were frequent during PI-triple therapy, and
so were therapeutic interventions. However, no patient
was lost during therapy.
Hematological toxicity is a specific feature of PI-triple
therapy, irrespective of which PI has been used (see
Table 4 for details). Thus, therapeutic interventions were
frequent and had to be performed in 36% (TVR), and
28% (BOC), respectively. The difference between the
high rate of anemia below 10 g/dL (45%), and the lower
rate of RBV reduction is most probably due to our pol-
icy, not to reduce RBV dosage in asymptomatic or oligo-
symptomatic patients with anemia with hemoglobin
values above 8.5 g/dL during the first phase of PI-triple
therapy. When at the EASL 2012 preliminary results
from the study of Poordad et al. [18] were published,
showing no difference in outcome if the RBV dosage is
significantly reduced, we changed our policy, and re-
duced RBV dosage at an earlier stage, contrary to the
treatment with PEG-IFN and RBV alone, where RBV re-
duction if ever possible should be avoided. Nevertheless,
no patient had to discontinue treatment due to anemia.
Severe rash was a rare event in former dual treatment
PR regime, and mostly was attributed to RBV. In PI-
triple therapy, pruritus and rash seem to constitute a PI
class effect, but in frequency and intensity much more
associated with TVR than with BOC: 11 of the TVR-
treated patients developed a severe rash, resulting in the
necessity of a complete discontinuation of treatment in
4 patients, and premature discontinuation of TVR alone
in additional 4 patients.Table 4 Hematological side effects in our “real-life” cohort




Hemoglobin < 10 g/dl
Hemoglobin < 8.5 g/dl




Therapeutic interventions due to hematological side effects
RBV dose reduction





*Blood transfusion encompassing at least 2 units of concentrated erythrocytes; **duDuring PI-triple therapy, hospital admissions were re-
quired in 23 patients (21 TVR-treated, 2 BOC-treated)
with some of those patients being hospitalized more
than once. Hospitalizations were due to infections (6 pa-
tients), rash (5 patients), hepatic decompensation (4 pa-
tients), and anemia (2 patients), respectively. Further
hospital admissions occurred due to a non-ST elevated
myocardial infarction (hemoglobin level in this patient
at that time point 12.9 g/dl), severe headaches, exsicco-
sis/ diarrhea, deep venous thrombosis, diagnosis and
treatment of lung cancer, and performance of LTx,
respectively.
During follow-up, four patients developed hepatocellu-
lar carcinoma. All of those patients had discontinued the
antiviral treatment prematurely due to side effects (n = 3)
or virological failure (n = 1) before the diagnosis of HCC
was made. Of those, one patient underwent LTx later on.
One patient was diagnosed with a malignant brain tumor
one year after successful conclusion of BOC-triple therapy,
and one patient died from an accident during follow-up.
Discussion
Our single center retrospective study analyzing efficacy,
safety and predictors of SVR 24 of PI-triple therapy in a
“real-life” setting shows overall SVR rates similar to
those, which had been achieved in the large clinical trials
leading to the approval of both TVR and BOC for treat-
ment of HCV, genotype 1, in 2011 [10-14,19,20]. Due to
the retrospective character of our study and the rela-
tively small number of patients, a comparison to the
large prospective clinical trials is only of limitedTVR BOC
n/N;% 68/102; 67% 18 29; 62%
n/N;% 18/102; 18% 2/29; 7%
n/N;% 47/102; 46% 12/29; 41%
n/N;% 21/102; 21% 5/29; 17%
g/dl 4.6 ± 1.7 4.8 ± 1.7
n/N;% 18/102; 18% 0/29
n/N;% 3/102; 4% 0/29
n/N;% 37/102; 36% 8/29; 28%
n/N;% 20/102; 20% 5/29; 17%
n/N;% 9/102; 9% 2/29; 7%
n/N;% 5/102; 5% 0/29
n/N;% 7/102; 7%** 1/29; 3%
n/N;% 7/102; 7% 0/29
e to leukopenia (n = 5), due to thrombocytopenia (n = 2). BL Base line.
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tween both subsets of patients being either treated with
BOC or TVR, respectively, no comparison between
both groups is possible. However, this disproportion in
distribution of both PI is present in other “real-life” co-
horts [21].
In PI-triple therapy, eRVR was the best predictor for
treatment success (SVR 24) both in our cohort and in
the large clinical trials. Patients, who displayed a min-
imal viral load (> LLOD, < LLOQ) at PI-TW 4 (TVR:
TW 4, BOC: TW 8) later on had a lower SVR rate com-
pared with patients, who had no detectable viral load at
this time-point (p = 0.0193). Thus, the achievement of a
negative HCV viral load at PI-TW 4 is crucial for assess-
ment of eRVR and further treatment decisions, including
response guided treatment. Furthermore, at least in our
cohort, TVR-patients, who showed a quantifiable viral
load at PI-TW4 (> LLOQ), always failed to achieve SVR
24 at least in our cohort (p < 0.0001).
With respect to several subgroups of patients accord-
ing to previous treatment, we found SVR rates in the
range of the large clinical trials. Interestingly, our group
of patients being previously treated with non-PEG-IFN
exhibited the same SVR 24 rate as our cohorts of treat-
ment naïve patients (80% [TVR], and 83% [BOC],
respectively). However, since there are no large numbers
of patients, and no controlled trials addressing non-
pegylated interferon experienced patients, treatment
decisions as shortening of treatment should be imple-
mented with caution in this subgroup, at least in
patients with a previous non-response to non-pegylated
interferon.
Non-response to a previous PR treatment still is a
negative predictor of treatment success in the era of first
generation PI (p = 0.0075), although in our TVR-
subgroup of patients we could achieve a SVR rate of
68%, thus exceeding the SVR rates noticed in the
REALIZE trial [12]. In the large BOC-trials, “null-
response” patients were omitted. However, in the differ-
ent treatment arms of the RESPOND-2 trial, SVR rates
of 40-52% could be achieved for the “partial response”
patients [14]. In our group of merged non-response pa-
tients, just one out of 8 patients achieved the SVR status
(13%). As a matter of fact, the small number of patients
again is a severe limitation to this evidence.
Almost all patients with a virological failure during
PI-triple therapy (13/14 patients) had a high viral load
(> 800.000 IU HCV RNA/ml) at baseline. However, no
statistical significance was achieved with respect to pre-
dictability of SVR 24, at least in our cohort.
Similar to the former standard treatment with PR, liver
cirrhosis was found to constitute a negative predictor of
SVR 24 also in PI-triple therapy [22], even though, at
least in our TVR cohort, far better SVR rates could beachieved in comparison to former PR treatment. Our
SVR 24 results varied between the two different PI-triple
therapy groups of patients: In the TVR group of patients
we could achieve SVR 24 rates of 71%, with side effects
being the main limiting factor in this cohort, leading in
25% of patients to treatment discontinuation. These data
exceed SVR 12 results from the French CUPIC cohort,
with decreased SVR 12 rates in comparison to other
subgroups of patients (SVR 12 in 132 out of 299
patients, or 44%; [16]), and other cohorts [22]. However,
due to the small number of patients in comparison to
these trials, these results should be interpreted with cau-
tion. With BOC-triple therapy, the CUPIC cohort
observed a SVR 12 of 38% (80/212; [16]), while in our
small cohort of patients with liver cirrhosis, merely two
out of seven patients achieved SVR. Importantly, pa-
tients with significant portal hypertension defined by a
baseline low platelet count (below 100/nl) seem not to
be suitable for a first-generation PI-triple therapy, since
almost all of those patients failed to reach EOT (11 out
of 15 patients), either due to virological failure, or due to
mostly severe side effects. This finding could also be
observed in the CUPIC study [23]. Therefore, an exclu-
sion of those patients from first-generation PI triple
therapy is a reasonable treatment decision due to the
disproportion between efficacy and potential harm of
those treatment regimes.
In our cohort, older patients achieved good SVR rates
(73% with TVR, and 80% with BOC, respectively). How-
ever, in aged patients, treatment failure reflects more the
intolerance to side-effects than the lack of virological
response to PI-triple therapy.
Of note, approximately half of treatment failures were
due to side-effect induced premature discontinuations.
Most of them occurred in the difficult-to-treat sub-
groups of cirrhotic patients or/and patients of older age
(14 out of 18 patients, who discontinued due to side
effects). While in the TVR-group of patients premature
discontinuations of treatment due to severe side effects
(rash, hepatic decompensation, infections, bleeding)
occurred regularly, such intense side effects in general
were not seen in the BOC-group of patients, but, how-
ever, in both groups the rates of discontinuations were
around 10%.
Unlike to the large clinical trials, in our TVR-“real-life”
cohort 5% (6/131) of patients had to be hospitalized
due to bacterial infections. Other “real-life” cohorts re-
ported severe infections in 2-9% of patients, with most
severe infections in the group of patients with liver cir-
rhosis [16,21,24].
Even if TVR and BOC both still are mentioned in the
current EASL treatment recommendations as of April
2014 with a half-sentence [25], in western countries the
time for first-generation PI-treatment seems to be over.
Werner et al. Virology Journal  (2015) 12:37 Page 10 of 11With the approval of Sofosbuvir, Dasabuvir, Simeprevir,
Paritaprevir, Daclatasvir, Ledipasvir, and Ombitasvir
[26-30], Interferon-free combinations are or will be
available with SVR rates exceeding 90% through all
genotypes. Importantly, these treatment regimens will
have a by far more favorable safety profile than the first-
generation PI-triple therapy with BOC and TVR.
However, since the new generation DAA possibly will
not be available or affordable in all countries, TVR and
BOC may find their niche in the treatment of certain
subgroups of patients, or regions of the world.Conclusion
In summary, in our retrospective analysis SVR 24 rates
of PI-triple therapy from the large prospective clinical
trials could be translated into “real-life”. As in the large
trials, eRVR is the strongest predictor of treatment suc-
cess. Furthermore, not to achieve a HCV viral load
below LLOQ at PI-TW 4 is a strong predictor of future
treatment failure. Pronounced side effects are frequent
during therapy and often need complex therapeutic in-
terventions. Importantly, patients with advanced portal
hypertension (platelets below 100/nl) should not be
treated with PI-triple therapy due to low efficacy and an
unfavorable safety profile.
Abbreviations
CUPIC: Compassionate use of protease inhibitors in cirrhotics; DAA: Direct-acting
antiviral agents; EOT: End of treatment; eRVR: Extended rapid virological response;
G-CSF: Granulocyte-colony stimulating factor; GPT: Glutamate-pyruvate
transferase; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus;
IFN: Interferon; ITT: Intention to treat; IU: International units; LLOD: Lower
limit of detection; LLOQ: Lower limit of quantification; LTx: Liver transplantation;
MELD: Model of end stage liver disease; PEG-IFN: Pegylated interferon;
PI: Protease inhibitor; PR: PEG-IFN plus RBV; RBV: Ribavirin; RNA: Ribonucleic acid;
RVR: Rapid virological response; SVR: Sustained virological response;
TVR: Telaprevir; TW: Treatment week.
Competing interests
The authors received no financial support. No funding source exists. The
authors have read the journal’s policy and declare the following conflicts
concerning Peg-Interferon alpha-2a (Roche), Peg-Interferon alpha-2b and
Boceprevir (Merck), Ribavirin (Roche, Merck), Telaprevir (Janssen-Cilag): CRW
received travel grants from Merck, Roche, and Janssen-Cilag, and lecture fees
from Roche; CF declares no conflict; DPE received travel grants from Merck,
and Roche, and lecture fees from Roche; NPM declares no conflict; UML
received travel grants from Merck, and Roche; CPB received travel grants
from Merck, Roche and Janssen-Cilag, and lecture fees from Merck, Roche,
and Janssen-Cilag.
Authors’ contributions
CRW, CF, CPB participated in the design of the study, gathered the data,
performed the statistical analysis and drafted the manuscript. RB carried out
the virological analyses and helped to draft the manuscript. DPE, ULM, and
NPM participated in the design of the study and helped to draft the
manuscript. All authors read and approved the final manuscript.
Author details
1Department of Gastroenterology, Hepatology, and Infectiology, University
Hospital Tübingen, Tübingen, Germany. 2Institute of Medical Virology,
University Hospital Tübingen, Tübingen, Germany.Received: 31 July 2014 Accepted: 10 February 2015
References
1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus
infection. Lancet Infect Dis. 2005;5(9):558–67.
3. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C
virus infection in Europe. J Hepatol. 2008;48(1):148–62.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med. 2002;347(13):975–82.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,
et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b
plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet. 2001;358(9286):958–65.
6. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al.
Sustained virological response: a milestone in the treatment of chronic
hepatitis C. World J Gastroenterol. 2013;19(18):2793–8.
7. Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, et al.
Pegylated interferon alpha plus ribavirin for the treatment of chronic
hepatitis C: a multicentre independent study supported by the Italian Drug
Agency. Dig Liver Dis. 2014;46(9):826–32.
8. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M,
et al. Effect of sustained virological response on long-term clinical outcome in
113 patients with compensated hepatitis C-related cirrhosis treated by
interferon alpha and ribavirin. World J Gastroenterol. 2007;13(42):5648–53.
9. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association
between hepatitis C infection and survival after orthotopic liver transplantation.
Gastroenterology. 2002;122(4):889–96.
10. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR,
Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C
virus infection. N Engl J Med. 2011;364(25):2405–16.
11. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT,
et al. Response-guided telaprevir combination treatment for hepatitis C virus
infection. N Engl J Med. 2011;365(11):1014–24.
12. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir
for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.
13. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med.
2011;364(13):1195–206.
14. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl
J Med. 2011;364(13):1207–17.
15. Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for
chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti
Infect Ther. 2014;12(7):763–73.
16. Hezode C, Fontaine H, Pol S, Dufour C, Barthe Y, Carrat F, et al. Efficacy and
safety of telaprevir or boceprevir in combination with peginterferon alfa/
ribavirin, in cirrhotics according to the age. Data from the CUPIC cohort
(ANRS CO20) Abstract #1845. Hepatology. 2013;58(S1):1092A.
17. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, et al.
Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the
German guidelines on the management of HCV infection. Z Gastroenterol.
2010;48(2):289–351.
18. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, et al.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related
anemia in patients with chronic hepatitis C virus genotype 1 infection–a
randomized trial. Gastroenterology. 2013;145(5):1035–44. e1035.
19. Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, et al.
Retreatment with telaprevir combination therapy in hepatitis C patients
with well-characterized prior treatment response. Hepatology.
2011;54(5):1538–46.
20. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH,
et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med.
2010;362(14):1292–303.
21. Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, et al. Safety
profile of boceprevir and telaprevir in chronic hepatitis C: Real world
experience from HCV-TARGET. J Hepatol. 2015;62(2):286–93.
22. Colombo M, Strasser S, Moreno C, Abrao Ferreira P, Urbanek P, Fernandez I,
et al. Sustained virological response with telaprevir in 1,078 patients with
Werner et al. Virology Journal  (2015) 12:37 Page 11 of 11advanced hepatitis C: the international telaprevir access program. J Hepatol.
2014;61(5):976–83.
23. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple
therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre
cohort of the French Early Access Programme (ANRS CO20-CUPIC) -
NCT01514890. J Hepatol. 2013;59(3):434–41.
24. Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI,
Urbanek P, et al. Safety and on-treatment efficacy of telaprevir: the early
access programme for patients with advanced hepatitis C. Gut.
2014;63(7):1150–8.
25. Pawlotsky JM, Aghemo A, Dusheiko G, Forns X, Puoti M, Sarrazin C. EASL
recommendations on treatment of hepatitis C 2014. http://www.easl.eu/
_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014.
26. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al.
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med. 2014;370(17):1594–603.
27. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily
simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive
genotype 1 hepatitis C: the randomized PILLAR study. Hepatology.
2013;58(6):1918–29.
28. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC,
et al. Sofosbuvir for previously untreated chronic hepatitis C infection.
N Engl J Med. 2013;368(20):1878–87.
29. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T,
Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or
untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.
30. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
N Engl J Med. 2014;370(16):1483–93.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
